Acelyrin Inc (SLRN) Return on Investment ROI from the first quarter of 2025 to first quarter of 2024 and for the year 2025, average high and low, overall ranking from Mar 31 2025 to Mar 31 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Acelyrin Inc   (NASDAQ: SLRN)


Acelyrin Inc's ROI from its first quarter of 2025 to the first quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Acelyrin Inc's ROI in the first quarter of 2025?
Acelyrin Inc recorded a cumulative net loss of $-269 million during 12 months ending in the first quarter of 2025, resulting in a negative return on investment (ROI) of -53.17%.

Within the Healthcare sector 538 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2024 from 3505 to 3625.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter
Y / Y Investment Change TTM -28.84 % -8.4 % 16.16 % 90.02 % 399.01 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 413 465 573 569 645
Return On Investment (TTM) -53.17 % -44.09 % -43.26 % -46.02 % -33.84 %
SLRN's Overall Ranking # 3625 # 3505 # 3544 # 3028 # 2676
Seq. Investment Change TTM -10.3 % -7.89 % -6.17 % -8.21 % 15.47 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -269 -248 -264 -300 -240

SLRN Company Profile >> Back to SLRN Roi Comparisons >> See Annual SLRN Return On Investment



Return On Investment SLRN's Ranking
Within: No.
Industry # 225
Sector # 539
Overall # 3625

Return On Investment Statistics
High Average Low
-9.76 %
-69.84 %
-266.49 %
(Jun 30 2023)   (Mar 31 2023)



  News about Acelyrin Inc Return on Investment ROI

Acelyrin Inc. Ramps Up Leadership Transition Amidst Financial Struggles

May 9, 2024



In a recent press release, Acelyrin Inc. announced a significant leadership transition within the company. Mina Kim has been appointed as the new Chief Executive Officer and will also join the Board of Directors. This change in leadership brings a fresh perspective and a wealth of experience to guide the company through its future endeavors.
However, alongside this leadership transition, Acelyrin Inc. also faces some concerning financial statistics. During the 12 months ending in the fourth quarter of 2023, the company recorded a cumulative net loss of $-382 million. This substantial loss resulted in a negative return on investment (ROI) of -62.1%. These figures indicate a significant challenge for the company to achieve profitability.

Agnes Lee Appointed as ACELYRIN's Senior Vice President of Investor Relations and Corporate Communications, Enhancing Transparency and Investor Engagement

February 15, 2024

ACELYRIN, INC. Boosts Investor Relations with the Appointment of Agnes Lee as Senior Vice President

ACELYRIN, INC., a leading healthcare company, has announced the appointment of Agnes Lee as Senior Vice President of Investor Relations and Corporate Communications. With over 25 years of experience in investor relations, communications, and operational and strategic finance in the public healthcare sector, Lee brings a wealth of knowledge and expertise to the company. This strategic move aims to strengthen ACELYRIN s communication efforts and effectively engage its investors and stakeholders. The appointment of Lee reflects the company s commitment to enhancing transparency and maximizing shareholder value.
Background:
ACELYRIN, INC. has been at the forefront of healthcare innovation, consistently delivering groundbreaking solutions to address critical medical challenges. However, as the company continues to expand its portfolio and diversify operations, effective communication becomes paramount. ACELYRIN recognizes the importance of maintaining a strong relationship with its investors and stakeholders through transparent and timely disclosures, as well as engaging communication strategies.





Financial Statements
Acelyrin Inc's I. Quarter Investments $ 413 Millions SLRN's Balance sheet
Acelyrin Inc's I. Quarter Income $ -55 Millions Quarterly SLRN's Income Statement
SLRN's Income by Division See SLRN's Income by Division


SLRN Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023


Total Investments in Millions 465 658 0 0 0
Y / Y Investment Growth -29.35 % - - - -
Net Income in Millions -248 -382 0 0 0
Y / Y Net Income Growth - - - - -
Annual Return On Investment -53.43 % -58.04 % - - -


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SLRN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SLRN's Competitors
Subscribers only: Roi for Acelyrin Inc's Suppliers
Subscribers only: Return On Investment for SLRN's Customers

Other Ratios
SLRN's Roa SLRN's Inventory Turnover Ratio SLRN's Growth Rates SLRN's Dividend Statistics
SLRN's Profitability Ratios SLRN's Asset Turnover Ratio SLRN's Dividend Growth
SLRN's Roe SLRN's Valuation Ratios SLRN's Financial Strength Ratios SLRN's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2025, within Healthcare Sector ROI

Date modified: 2026-09-26T07:42:31+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.